Pyxis Oncology Inc (PYXS) Stock: Navigating Drops and Gains

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Pyxis Oncology Inc’s current trading price is -35.26% away from its 52-week high, while its distance from the 52-week low is 231.85%. The stock’s price range for this time frame has been between $1.35 and $6.92. The trading volume of the company’s shares in the Healthcare reached around 411.07 for the day, which was evidently higher than the average daily volume of 3.95 over the last three months.

The market performance of Pyxis Oncology Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $6.92 on 03/30/23, with the lowest value for the same timeframe being $1.35, recorded on 11/24/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

How Financial Performance Impacts Market Capitalization

Pyxis Oncology Inc (PYXS) has experienced a quarterly rise of 174.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 198.42M.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.08, with a change in price of +2.44. Similarly, Pyxis Oncology Inc recorded 314,564 in trading volume during the last 100 days, posting a change of +119.61%.

How PYXS’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for PYXS stands at 0.16. Similarly, the long-term debt-to-equity ratio is also 0.15.

PYXS Stock Stochastic Average

The raw stochastic average for Pyxis Oncology Inc over the last 50 days is presently at 98.04%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 97.52%. Further, the company’s Stochastic %K and %D values for the last 20 days were 80.97% and 76.26%, respectively.

PYXS Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The index has shown a price gain of 148.89% this year. Over the last six months, there has been a weaker performance of 85.12%. The price of PYXS fallen by 86.67% during the last 30 days period. For the last 5-days stocks have improved 21.74%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts